Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Portfolio Pulse from
Cytokinetics (CYTK) reported a Q4 loss of $1.26 per share, missing the Zacks Consensus Estimate of a $1.22 loss. This is an improvement from the $1.38 loss per share a year ago.
February 27, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cytokinetics reported a Q4 loss of $1.26 per share, missing the expected loss of $1.22. This is an improvement from the previous year's $1.38 loss.
Cytokinetics' Q4 loss was larger than expected, which is typically negative for stock prices. However, the loss was smaller than the previous year, indicating some improvement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100